IMMUNOME SEES DISEASE THROUGH THE LENS OF THE HUMAN B CELL
AND HARNESSES THE NATURAL CURATIVE PROPERTIES OF THE HUMAN BODY
TO DISCOVER MONOCLONAL ANTIBODIES (mAbs)
Immunome has industrialized both its hybridoma library generation and screening capabilities. We can generate up to 10,000 hybridomas quickly from each patient and screen those antibodies in ELISA, flow cytometry, and customizable protein microarray formats against a minimum of 100 different antigen sources. Our Antibody Discovery Engine is built on several key features:
The single-step, non-biased and stable capture of thousands of patient-derived B cells and the antibodies they produce; and
The simultaneous interrogation of each individual antibody against a complex mixture of disease-related antigens.
We generate million of data points from each patient, which allows us to rapidly focus on the very few antibody-antigen pairs with the potential to most effectively fight the disease. This approach helps identify previously-unexplored disease targets and gives Immunome an important advantage over approaches that focus only on well-known targets.
Immunome’s research is yielding interesting targets in the oncology, anti-viral and anti-bacterial spaces. In addition to our internal development programs, we also intend to partner with pharmaceutical companies, universities, government agencies, and global health organizations to develop new treatments that will significantly impact human health.